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Abstract
Objective. Stage I colorectal carcinomas display a highly variable behavior which is not accurately predicted by the available
prognostic markers. CD133 is considered a useful marker to identify the so-called cancer stem cells in colorectal cancers
(CRCs) and its expression has been shown to have prognostic signiﬁcance in CRC patients. This study aimed to verify whether
immunohistochemical evaluation of CD133 might correlate with the progression risk of stage I CRC patients. Material and
methods. Expression levels of the CD133 molecule were analyzed and compared in two series of stage I surgically resected
CRC patients showing disease progression and death for the disease and patients with no evidence of disease progression after
at least 6 years after surgery. Results. A positive staining for CD133 was detected in 52% of the cases with poor prognosis and
only in 9% of the group with good prognosis, and this difference was highly signiﬁcant (p < 0.001). A signiﬁcant correlation was
detected between CD133 expression and histological parameters, such as tumor budding, vascular invasion, and presence of
lymph node micrometastases but not tumor grading, gender, and age. Disease-free survival and cancer-speciﬁc survival of
CD133 negative tumors were signiﬁcantly longer compared to positive cases. In multivariate analyses, CD133 staining
conﬁrmed to be a predictor of shorter survival independent from vascular invasion but not from lymph nodes micrometastases.
Conclusions. These ﬁndings demonstrate that CD133 immunostaining is a useful predictor of high risk progression in stage I
CRC patients and might help to identify patients eligible for adjuvant chemotherapy.
Key Words: adjuvant therapy, cancer stem cells, CD133, prognosis, stage I colon cancer
Introduction
CD133, also known as prominin-1, a transmembrane
pentaspan molecule, is considered a putative stem cell
marker expressed in several normal and cancer tissues
[1]. Numerous studies have demonstrated that surface
expression of CD133 identiﬁes a subpopulation of
tumor-initiating cells, having the properties of self-
renewal, proliferation, andmultilineage differentiation
in a variety of human cancer tissues, including colon
cancer [2-4].Although the exact role(s) of themolecule
in human colorectal cancer (CRC) tumorigenesis
remain unknown [5,6],CD133 is presently considered
a useful marker to identify cancer stem cells (CSC) in
CRCs and its expression level has been shown to have
prognostic signiﬁcance in colon cancer patients [7-11].
Colon cancer represents a leading cause of cancer-
related deaths in Western countries and, although
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multiple therapeutic approaches are available for its
treatment, its management is somehow complicated
by the variable behavior of the disease. Indeed, prog-
nostic stratiﬁcation of the disease is mainly based on
its anatomic extent, as assessed by the TNM staging,
which strongly affects patients’ survival [12]. How-
ever, TNM is not able to accurately predict clinical
outcome of early lesions, such as stage I carcinomas.
Stage I colorectal carcinoma indicates a disease con-
ﬁned within the muscular wall of the large bowel
without inﬁltration of local structures, in the absence
of lymph nodes or distant metastasis. This category
can be further stratiﬁed into two subgroups: T1,
tumors spreading through the muscularis mucosae
into the submucosa and T2, tumors inﬁltrating the
muscular wall. Stage I CRCs display an overall 5-year
survival around 80–90% and are considered at very
good prognosis. However, a small subset of stage I
CRC patients display relapses and disease progression
and available prognostic markers are not able to
identify this subgroup of patients which might beneﬁt
from a more aggressive (i.e., adjuvant therapies)
treatment [12]. Thus, the development of new prog-
nostic markers able to identify stage I CRC patients at
high risk of progression is a major topic in CRC
research and is becoming increasingly needed as
new treatment options become available. CD133
has been reported to be a potentially important prog-
nostic marker in CRC patients being able to speci-
ﬁcally mark cells responsible for tumor initiation as
well as tumor relapse and metastasis. In the present
study, CD133 expression levels were analyzed by
immunostaining in selected specimens of stage I
human primary CRCs, including patients deceased
because of disease progression within 10 years after
surgery and patients still alive with no evidence of
disease progression after a 6 years or longer follow up.
The aim of the study was to verify whether
CD133 could be able to identify subgroups of stage
I CRC patients with different prognosis. Moreover,
the potential prognostic signiﬁcance of CD133 was
also evaluated on the overall population of stage I
patients included in the study.
Materials and methods
Patient characteristics and tissue samples
The study included 95 patients, selected from
518 consecutive patients with stage I colorectal
adenocarcinoma, diagnosed between January 1989
and December 2004 and collected in a specialized,
population-based, Colorectal Cancer Registry of
the District of Modena, Italy. Selection of patients
was previously described [13]. All had undergone
curative surgery for CRC at the Division of Surgery,
School of Medicine, University of Modena and
Reggio Emilia, Modena, Italy, and none of them
had received chemotherapy. They were selected
according to the following criteria: ﬁrst group: all
patients who died due to the progression of the disease
within 10 years from the diagnosis (n = 25); second
group: a randomized set of patients registered in the
same years of cases with an excellent clinical outcome
still alive after at least 6 years from surgery with no
evidence of disease progression or relapses (n = 70).
Informed consent was obtained from all subjects [13],
and the study was approved by the Research
Ethics Committee of the University of Modena and
Reggio Emilia, Modena, Italy. Clinic-pathological
data were retrieved from the archives of the Depart-
ment of Pathology, University of Modena and Reggio
Emilia, Modena, Italy. Histological grade was estab-
lished according to the WHO classiﬁcation system
criteria. All cases and controls were reviewed
by two expert pathologists, and in none of them
metastases were detected in the lymph nodes by
conventional staining with hematoxylin and eosin.
Lymph nodes were analyzed for the presence of
micrometastases by immunohistochemistry using a
monoclonal antihuman pan-cytokeratin antibody
(DAKO CK, Corpintreia, CA, USA), as previously
reported [13].
Immunohistochemical analysis
Immunohistochemicalanalyseswereperformedonrou-
tinely processed, formalin-ﬁxed, parafﬁn-embedded
(FFPE) tissues employing an avidin–biotin complex
immunoperoxidase technique, as previously described
[14,15].Brieﬂy, successive5mmtissuesectionswerecut
fromblocks of the primary tumors and the lymph nodes
selected for the presence of representative lesions and
mounted on charged and pre-cleaned slides. Sections
were de-waxed, rehydrated, and then microwave pre-
treated (10 mM sodium citrate, pH 6.0) for antigen
retrieval.Eachslidewas then incubatedovernight at4C
with the primary antibody. A colon carcinoma with
known positive immunostaining for CD133 served as
a positive control. Positive reaction was deﬁned by
the presence of at least 50% of cancer cells displaying
either membranous and/or cytoplasmic staining [14].
A speciﬁc polyclonal anti-CD133 antibody (SantaCruz
Biotechnology, SantaCruz, CA,USA; 1:100) was used
for the staining.We did not notice any difference in the
immunoreactivity between older and younger FFPE
samples and comparable results but with a weaker
staining were obtained using the monoclonal
AC133 antibody (Miltenyi Biotec, Bergisch Gladbach,
Germany; 1:10) (data not shown).
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All scoring and interpretations of the results were
made by two of the authors independently (MM and
LRB) without knowledge of other clinicopathological
variables and no cases with discrepant scoring were
recorded.
Statistical analysis
The association between molecular and clinico-
pathological parameters were calculated using con-
tingency table methods and tested for signiﬁcance
using the Pearson’s chi-square test. Patients were all
uniformly followed-up at our Institution and disease-
free survival (DFS) was deﬁned as the interval
between surgery and the ﬁrst documented evidence
of recurrences in local-regional area and/or distant
sites. Cancer-speciﬁc survival (CSS) was deﬁned as
the interval between surgery and death from the
disease. Disease-free and cancer-speciﬁc survival
curves were calculated using the Kaplan–Meier
method and the log-rank test was used to compare
survival curves. Univariate and multivariate relative
risks were calculated using the Cox proportional
hazards regression. All calculations were performed
using the STATA statistical software package (Stata
Corporation, College Station, Texas, TX, USA) and
the results were considered statistically signiﬁcant,
when the p value was £0.05.
Results
The overall median age of stage I CRC patients
analyzed in this study was 70 years (range, 43–90
years; mean, 69.4 ± 10.5), and they included 53 males
(mean age 69.9 ± 11.2) and 42 females (mean age
68.8 ± 9.5). The ﬁrst group (n = 25, cases) included
14 males and 11 females with a median age of 71 years
(range, 55–90 years; mean, 72.04 ± 10.20) who died
from the disease within 10 years after surgery (median
overall survival was 50 months; range, 12–119). The
second group (n = 70, controls) included 39 males
and 31 females with a median age of 70 years (range,
43–86 years; mean, 68.51 ± 10.48) registered in
the same years of cases but still alive after more
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Figure 1. Examples of CD133 immunohistochemical staining in human colorectal samples. (A and B) Normal colonic mucosa. Note the rare
(!) positivity for CD133 (400). (C) A moderately differentiated adenocarcinoma displaying a diffuse staining for CD133 (200). (D and E)
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than 6 years from surgery (median follow up was
108 months; range, 72–144). The same population
of patients were previously characterized [13] in detail
and reported to display vascular invasion (deﬁned as
the presence of tumor cells in lymphatic or venous
microvessels) in four (5.7%) controls and 13 (52%)
cases (p < 0.001) and cytokeratin-positive micro-
metastasis in one (1.4%) control and in 18 of
25 (72%) stage I CRC patients who died of the disease
(p < 0.001) [13].
Using the anti-CD133 antibody, both membrane
and cytoplasmic staining was detected in positive cells
(Figure 1). Scattered positive cells were detected on
the bases of the crypts in normal colonic mucosa
(Figure 1A–B). In cancers, a diffuse and heteroge-
neous staining was clearly evident in tumor cells
and samples were considered positive, when at least
50% of cancer cells displayed a positive staining
(Figure 1C–F). A positive staining for CD133 was
detected in 13 of 25 (52%) of the cases with poor
prognosis and only in 6 of 70 (9%) of the group with
excellent prognosis, and this difference was highly
signiﬁcant (p < 0.001).
Overall, 76 (80%) of the 95 patients included in
this study were negative for CD133, while 19 (20%)
displayed a positive staining. Considering the entire
subset of patients, a signiﬁcant correlation was
detected between CD133 expression and histological
parameters such as tumor budding in the actively
invasive frontal region of the tumor (p < 0.001), vas-
cular invasion (p < 0.003), and presence of lymph
node micrometastases (p < 0.001) but not tumor
grading, gender, and age (Table I and data not
shown).
Twelve (16%) of the 76 CD133 negative and
13 (68%) of the 19 CD133 positive patients displayed
a disease progression and died of disease during
the period of follow-up, and this difference was
signiﬁcant (p = 0.001, see Table I). As expected,
mean DFS (109.8 vs. 62.3 months) as well as CSS
(113.3 vs. 80.2 months) of CD133 negative tumors
were longer compared to positive cases, and the
differences were signiﬁcant (p = 0.001 for DFS and
0.002 for CSS) as conﬁrmed by the Kaplan–Meier
curves of DFS and CSS, which also displayed a
signiﬁcant separation between the two groups of
patients (p = 0.001 by log-rank test) (Figure 2).
As previously mentioned, the stage I CRCs
included in this study were previously characterized
for several parameters (i.e., tumor dimension, pattern
of growth, degree of differentiation, lymphomono-
cytic peritumoral inﬁltrate, tumor budding, vascular
invasion, and the presence of cytokeratin positive
micrometastasis in lymph nodes) and only the pres-
ence of micrometastasis and vascular invasion – but
no other clinical or biological parameter – displayed
an association with survival [13]. Indeed, 18 (95%) of
the 19 patients with micrometastasis and 7 (9%) of the
76 patients in which it was not possible to detect
cytokeratin positive cells in lymph nodes displayed
a disease progression during the period of follow-up,
and the Kaplan–Meier curves of both DFS and
CSS displayed a signiﬁcant separation between the
two groups of patients (p = 0.001 by log-rank test)
(data not shown). Similarly, 13 (76%) of the
17 patients with vascular invasion and 12 (15%) of
the 78 patients with no vascular invasion displayed a
disease progression during the period of follow-up,
and the Kaplan–Meier curves of both DFS and
CSS displayed a signiﬁcant separation between the
two groups of patients (p = 0.001 by log-rank test)
(data not shown).
In a multivariate analysis performed by building a
Cox hazards model that included all the factors (vas-
cular invasion, micrometastase, and CD133 staining)
found to be associated with disease progression in the
univariate analyses, positive CD133 staining did not
conﬁrm to be an independent predictor of shorter
DFS (p = 0.102; C.I. 0.870–4.672; RR = 2.016) nor
of overall survival (p = 0.105; CI: 0.865–4.603;
RR = 1.996) compared to vascular invasion and
micrometastasis (Tables II and III). However, it is
noteworthy that CD133 staining did conﬁrm to be an
independent predictor of shorter DFS (p = 0.102; CI:
0.870–4.672; RR = 2.016) as well as of overall survival
(p = 0.105; CI: 0.865–4.603; RR = 1.996) compared
to vascular invasion when a second Cox hazards
model was built that included only these two variables
but not micrometastasis (Tables II and III).
Table I. CD133 expression in relation to clinical and pathological
parameters in a series of 95 stage I CRCs.
Total
Negative
n (%)
Positive
n (%) p Value
Micrometastases
Present 19 9 (47) 10 (53)
Absent 76 67 (88) 9 (12) 0.001
Tumor budding
Present 30 16 (53) 14 (47)
Absent 65 60 (92) 5 (8) 0.001
Vascular invasion
Present 16 8 (50) 8 (50)
Absent 79 68 (86) 11 (14) 0.003
Tumor grading
G1 26 22 (85) 4 (15)
G2/G3 69 54 (78) 15 (22) n.s.
Follow-up
Progression 25 12 (48) 13 (52)
Stable disease 70 64 (91) 6 (9) 0.001
Abbreviation: n.s. = not signiﬁcant.
1214 L. R. Bonetti et al.
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Discussion
The present study represents an extension of a previous
report focused on the identiﬁcation of prognostic
factors useful for a better stratiﬁcation of stage I
CRC patients [13]. Indeed, stage I (Dukes’ A) carci-
nomas usually show an excellent clinical outcome and
are solely treated by surgical resection since, at present,
the accepted guidelines recommend adjuvant chemo-
therapy only for treatment of stage III and selected
cases of stage II patients with CRC. However, a small
fraction of stage I patients die of recurrence or metas-
tases and available prognostic factors do not allow the
identiﬁcation of high risk patients [12]. Thus, new
markers are needed for a better prognostic stratiﬁcation
of stage I patients. To this aim, we took advantage of a
specialized CRC registry to identify all patients with
stage I CRC and, among them, those who died of
the disease, which undoubtedly represent a small frac-
tion of all incident cases. We believe that the patients
(n = 25) with a worse prognosis included in this study
are fully representative of the subset of stage I patients
at high risk of disease progression and they were
matched to patients registered in the same years
of cases but still alive after more than 6 years from
surgery.
To our knowledge, this is the ﬁrst report analyzing
CD133 expression in a subset of stage I CRC patients
selected on the basis of clinical outcome. We found
that 52% of the cases with poor prognosis and 9% of
the group with good prognosis displayed a positive
staining for CD133, and this difference was highly
signiﬁcant (p < 0.001). Moreover, considering the
overall population of patients included in this study,
positive staining for CD133 correlated strongly with
the occurrence of lymph node micrometastases and
unfavorable histological features, including tumor
budding and vascular invasion (Table I), and
displayed a signiﬁcant relationship with high risk of
disease progression in univariate analyses (Figure 2).
These observations are consistent with the CSC
model of tumorigenesis suggesting that tumors are
hierarchically organized like normal tissues and
that only a rare subpopulation of undifferentiated
cells has the unique biological properties necessary
for tumor initiation, maintenance, and spreading
[16]. As previously mentioned, CD133 is presently
considered a useful marker to identify CSC in CRCs,
and it is expected to identify cells which have the
ability to initiate tumor growth and would represent
the majority responsible of tumor progression, inclu-
ding colonization of distant organs and metastasis [1].
Moreover, the results of the present study are in
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Figure 2. Kaplan–Meier curves for disease-free (upper panel) and
overall (lower panel) survival in a series of 95 stage I CRC patients.
Patients were stratiﬁed by CD133 expression (see text for details).
Table II. Contribution of various potential prognostic factors to
DFS by Cox regression analysis in stage I CRC patients.
Variable Risk ratio
95% Conﬁdence
interval p Value
Model 1
Micrometastasis* 12.157 4.465–33.105 0.001
Vascular invasion# 3.316 1.413–7.784 0.006
CD133** 2.016 0.870–4.672 0.102
Model 2
Vascular invasion# 5.691 2.347–13.797 0.001
CD133** 3.534 1.471–8.489 0.005
*The risk ratio is given as presence versus absence of
micrometastases.
#The risk ratio is given as presence versus absence of vascular
invasion.
**The risk ratio is given as positive versus negative tumors.
CD133 in stage I colon cancer 1215
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agreement with previous reports suggesting a prog-
nostic signiﬁcance of CD133 immunohistochemical
evaluation in CRC patients [7-11] and the observed
relationship between CD133 expression and histolo-
gical parameters, such as vascular invasion and the
presence of lymph node micrometastases, warrants
further studies to analyze whether cancer cells
in vascular invasion and micrometastases actually
express CD133.
In multivariate analyses performed by building a
Cox hazards model including all the factors (vascular
invasion, micrometastase, and CD133 staining)
found to be associated with disease progression in
the univariate analyses, positive CD133 staining did
not conﬁrm to be an independent predictor of worse
prognosis compared to vascular invasion and micro-
metastasis but did show an independent association
with survival when micrometastasis was not included
in the hazards model (Tables II and III). We previ-
ously reported that lymph nodal micrometastases
detected by immunostaining using an anti-cytokeratin
monoclonal antibody could be detected in the majo-
rity of the resected specimens of patients with stage I
tumors who died of the disease within 10 years from
surgery and that by Cox regression analysis, micro-
metastasis, and vascular invasion, but no other clinical
or biological parameter, showed an independent
association with survival when both are included in
the model, with the presence of micrometastasis dis-
playing the highest RR (see Tables II and III) [13].
Thus, micrometastasis can be considered a useful
parameter for the identiﬁcation of high risk stage I
CRC patients for which adjuvant chemotherapy
could be a valuable option. However, conﬂicting
results have been reported on the prognostic signi-
ﬁcance of micrometastases for stage I patients
[17-19,13,20]. Several factors can explain such dis-
crepancies, including different techniques used for
their identiﬁcation (IHC or DNA-based techniques),
different antibodies (i.e., different anticytokeratin
antibodies) as well as differences in the number
and methods (i.e., number of sections for node)
used to search for occult metastases. In our study,
pathologists performed a complete analysis of all
lymph nodes which could be detected and the isolated
nodes were cut entirely at intervals of 200 mm until no
more lymph node was available [13]. This meticulous
approach, however, is extremely tedious and time-
consuming and likely not easy to be performed on a
routine basis. Thus, the availability of a prognostic
marker which could be performed directly on the
surgical tumor specimen using a simple, immunohis-
tochemical technique appears as an extremely useful
and promising factor for the identiﬁcation of stage I
CRC patients at high risk of disease progression who
might beneﬁt of an adjuvant therapy following surgi-
cal resection. The introduction of CD133 immunos-
taining on a routine basis, of course, is not expected to
be easily achieved. Several problems remain to be
resolved, and ﬁrst of all it will be important to reach
a consensus agreement on the antibody to be used for
the analysis as well as the criteria for the evaluation of
the staining, since different approaches have been
reported in the literature [7-11]. Once these problems
will be solved, CD133 has the potentiality to become
an important prognostic factors in stage I (and maybe
stage II which also represent a challenging group)
CRC patients useful for a better management of
such patients.
In conclusion, we investigated CD133 expression
in a subset of stage I CRC patients and demonstrated
a clear correlation of its expression with other prog-
nostic indicators as well as with the clinical outcome
of patients. Stage I CRC patients are considered a
good prognosis at diagnosis and undergo potentially
curative surgery. However, a subset of them (up to
10%) [12] experience cancer progression with the
development of recurrences/distant metastases which
are associated with a signiﬁcantly worse prognosis and
shorter survival. The results of the present study
suggest that increased CD133 expression is a useful
prognostic marker for stage I CRC patients. These
ﬁndings will certainly be of interest, considering the
need of useful prognostic indicators that can accu-
rately predict the clinical outcome of patients with
localized CRC. However, it has to be underlined that
the population studied was too small to allow a
conclusive and deﬁnitive evaluation of the prognostic
signiﬁcance of CD133 expression level in these
patients. Thus, additional studies on a larger series
of cases are warranted to conﬁrm these results and to
further elucidate the role(s) of CD133 in the deve-
lopment and progression of CRC and its suitability
as a prognostic biomarker predictive of cancer
Table III. Contribution of various potential prognostic factors to
overall survival by Cox regression analysis in stage I CRC patients.
Variable Risk ratio
95% Conﬁdence
interval p Value
Model 1
Micrometastasis* 11.006 4.125–29.362 0.001
Vascular invasion# 3.751 1.597–8.812 0.002
CD133** 1.996 0.865–4.603 0.105
Model 2
Vascular invasion# 6.260 2.620–14.959 0.001
CD133** 3.331 1.407–7.888 0.006
*The risk ratio is given as presence versus absence ofmicrometastases.
#The risk ratio is given as presence versus absence of vascular
invasion.
**The risk ratio is given as positive versus negative tumors.
1216 L. R. Bonetti et al.
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aggressiveness and patient outcome. If conﬁrmed
on larger cohorts of patients, these ﬁndings could
have therapeutic implications by helping to identify
patients at higher risk of progression and death from
the disease who would beneﬁt most from a systemic
adjuvant treatment after surgical resection. Moreover,
CD133 might well be a candidate molecular target for
the development of new therapeutic interventions if a
direct role of the molecule in the process of tumor
development and progression will be demonstrated in
colon tumorigenesis.
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